1-20 of 6,996 results for member:"Stephen O'Brien"
Librarians' tools
- Search time
- 1.312 seconds
- Solr query time
- 0.015 seconds
- Search query
- member:"Stephen O'Brien"
- We searched for
- member_ses:302707
Type
House
Session
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for International Development, what her Department's spend on malaria control was in 2013-14.
To ask the Secretary of State for International Development, what her Department's spend on malaria control was in 2013-14.
In 2013-14 we estimate that the UK Government spend on malaria control was £536 million. This has been calculated using the methodology detailed in the Malaria Framework of Results. This can be found at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/67642/malaria-framework-for-results.pdf.
Malaria death rates have been falling globally since 2010 and the UK investments have significantly contributed to this achievement. According to analysis of current trends by the World Health Organization, by 2015, six high burden countries are on track to halve malaria mortality from a 2009 baseline and another six high burden countries are on track to achieve a 40-50% reduction in malaria attributable deaths. More detail on the UK’s achievements can be found at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/410980/DFID_Mid-Year_Report_Achievements_Annex.pdf.
It is a privilege to follow the right hon. Member for Neath (Mr Hain) as he and I share something a little unusual, in that we have travelled from remote parts of Africa to find ourselves both sent to this place and now departing on the same day.
The abruptness of...
It is a privilege to follow the right hon. Member for Neath (Mr Hain) as he and I share something a little unusual, in that we have travelled from remote parts of Africa to find ourselves both sent to this place and now departing on the same day.
The abruptness of...
To ask the Secretary of State for Health, pursuant to the Answer of 3 March 2015 to Question 225373, if he will make it his policy that GPs should be able to commission cervical smear tests for diagnostic purposes to investigate presenting symptoms outside the routine screening timeframes; and what...
To ask the Secretary of State for Health, pursuant to the Answer of 3 March 2015 to Question 225373, if he will make it his policy that GPs should be able to commission cervical smear tests for diagnostic purposes to investigate presenting symptoms outside the routine screening timeframes; and what...
A smear test is primarily used for screening purposes, and is unlikely to be appropriate when a woman has gynaecological issues that are symptomatic of cancer.
In such cases the National Institute for Health and Care Excellence Referral Guidelines for Suspected Cancer (2005) are available to help general practitioners (GPs) assess when it is appropriate to refer patients for suspected cancer, including cervical cancer. The Guidelines make clear recommendations in relation to gynaecological cancer, and state that:
“A patient who presents with symptoms suggesting gynaecological cancer should be referred to a team specialising in the management of gynaecological cancer, depending on local arrangements.”
In relation to cervical cancer the guidelines make clear that a smear test is not required before referral:
“In patients found on examination to have clinical features that raise the suspicion of cervical cancer, an urgent referral should be made. A cervical smear test is not required before referral, and a previous negative cancer smear result is not a reason to delay referral.”
Therefore, when a woman is experiencing gynaecological problems which are symptomatic of gynaecological cancer, their GP would be expected to refer them to the appropriate specialist without needing to conduct a smear test.
To ask the Secretary of State for Health, if he will change guidelines on cervical smear tests to permit GPs to conduct such tests on women outside of routine screening time frames, if the GP believes that such tests are necessary to investigate presenting symptoms.
To ask the Secretary of State for Health, if he will change guidelines on cervical smear tests to permit GPs to conduct such tests on women outside of routine screening time frames, if the GP believes that such tests are necessary to investigate presenting symptoms.
A cervical screening test is a population screening test, not a diagnostic test, and is therefore not appropriate for women with symptoms. Waiting two weeks for a smear test result could delay examination by a gynaecologist. The Department has published guidance for general practitioners (GPs) on managing young women aged 20-24 with abnormal vaginal bleeding. This is available at:
http://www.cancerscreening.nhs.uk/cervical/publications/doh-guidelines-young-women.pdf
Information for women of all ages on the symptoms of cervical cancer is available on the NHS Choices website at:
http://www.nhs.uk/conditions/cancer-of-the-cervix/pages/introduction.aspx
The Department advises women who are concerned about cervical cancer to speak to their GP.
rose—
rose—
As I am sure the hon. Lady is aware, the amazing, incredible leadership of the United Kingdom, straddling both parties’ times in office, is much admired around the world. I happen to have just come back from speaking at an event in Davos, where our leadership, through a unity of...
As I am sure the hon. Lady is aware, the amazing, incredible leadership of the United Kingdom, straddling both parties’ times in office, is much admired around the world. I happen to have just come back from speaking at an event in Davos, where our leadership, through a unity of...
As the Secretary of State knows, I had some involvement in the decision on Burundi. The shadow Minister cites Burundi. She should be aware that there was a specific project on which we were asked to deliver on a bilateral basis. It was a very effective project, because we delivered...
As the Secretary of State knows, I had some involvement in the decision on Burundi. The shadow Minister cites Burundi. She should be aware that there was a specific project on which we were asked to deliver on a bilateral basis. It was a very effective project, because we delivered...
I welcome this debate and am enthusiastic about the opportunity to discuss what should come after the success of the MDGs and SDGs in galvanising the world in this regard. I was naturally saddened by the tone of, and some of the expressions in, the motion, which are unnecessarily divisive....
I welcome this debate and am enthusiastic about the opportunity to discuss what should come after the success of the MDGs and SDGs in galvanising the world in this regard. I was naturally saddened by the tone of, and some of the expressions in, the motion, which are unnecessarily divisive....
It was Lord Lipsey who opposed it. Labour!
It was Lord Lipsey who opposed it. Labour!
My right hon. Friend will be aware that the proposals from the panel the Prime Minister co-chaired included 12 universal goals and national targets, which have been taken forward in the brief that Ban Ki-Moon issued six months later. My right hon. Friend will be aware, given the point that...
My right hon. Friend will be aware that the proposals from the panel the Prime Minister co-chaired included 12 universal goals and national targets, which have been taken forward in the brief that Ban Ki-Moon issued six months later. My right hon. Friend will be aware, given the point that...
To ask the Secretary of State for Health, if he will ensure that all monies received from industry rebate payments under the Pharmaceutical Price Regulation Scheme are utilised for the prescribing of medicines by NHS England.
To ask the Secretary of State for Health, if he will ensure that all monies received from industry rebate payments under the Pharmaceutical Price Regulation Scheme are utilised for the prescribing of medicines by NHS England.
In England, Pharmaceutical Price Regulation Scheme (PPRS) payments are taken into account in the allocations to NHS England through the Mandate. All the payments will go back into spending on improving patients’ health and care.
The NHS England budget for 2015-16 already takes account for money anticipated from higher than expected PPRS payments. The Mandate for 2015-16 has a set firm NHS England budget for 2015-16, which is £3billion (3%) higher than its budget for 2014-15. This increase takes into account a number of things, including additional funding for the National Health Service announced in the Autumn Statement and the fact that the PPRS payment in 2015-16 is now forecast to be higher than originally expected.
It will be up to NHS England how they split that overall budget between clinical commissioning groups, specialised commissioning etc. Following normal Government accounting rules there is no separately identified ring-fenced funding stream associated with the PPRS payment.
The PPRS helps all member companies to compete globally by providing stability in United Kingdom prices. It includes a number of initiatives to help speed uptake of medicines approved by National Institute for Health and Care Excellence in the NHS. Sales of new active substances launched on or after 1 January 2014 are exempt from payments though still included in the overall limit on growth and the payments made by industry as a whole. This recognises and rewards innovation.
Net sales growth from the first nine months of 2014 compared to 2013 was 5.9 per cent. This was higher than the agreed forecast growth of 3.87 per cent. and shows that patients are benefitting from greater access to branded medicines. Most companies have enjoyed growth in sales in 2014, with over 40 per cent. of companies having double-digit growth rates.
To ask the Secretary of State for Health, what recent assessment he has made of the effect of industry rebate payments under the Pharmaceutical Price Regulation Scheme (PPRS) on improving patients' access to innovative medicines; and what estimate he has made of the additional number of innovative medicines prescribed as...
To ask the Secretary of State for Health, what recent assessment he has made of the effect of industry rebate payments under the Pharmaceutical Price Regulation Scheme (PPRS) on improving patients' access to innovative medicines; and what estimate he has made of the additional number of innovative medicines prescribed as...
In England, Pharmaceutical Price Regulation Scheme (PPRS) payments are taken into account in the allocations to NHS England through the Mandate. All the payments will go back into spending on improving patients’ health and care.
The NHS England budget for 2015-16 already takes account for money anticipated from higher than expected PPRS payments. The Mandate for 2015-16 has a set firm NHS England budget for 2015-16, which is £3billion (3%) higher than its budget for 2014-15. This increase takes into account a number of things, including additional funding for the National Health Service announced in the Autumn Statement and the fact that the PPRS payment in 2015-16 is now forecast to be higher than originally expected.
It will be up to NHS England how they split that overall budget between clinical commissioning groups, specialised commissioning etc. Following normal Government accounting rules there is no separately identified ring-fenced funding stream associated with the PPRS payment.
The PPRS helps all member companies to compete globally by providing stability in United Kingdom prices. It includes a number of initiatives to help speed uptake of medicines approved by National Institute for Health and Care Excellence in the NHS. Sales of new active substances launched on or after 1 January 2014 are exempt from payments though still included in the overall limit on growth and the payments made by industry as a whole. This recognises and rewards innovation.
Net sales growth from the first nine months of 2014 compared to 2013 was 5.9 per cent. This was higher than the agreed forecast growth of 3.87 per cent. and shows that patients are benefitting from greater access to branded medicines. Most companies have enjoyed growth in sales in 2014, with over 40 per cent. of companies having double-digit growth rates.
To ask the Secretary of State for Health, what support is in place for the provision of public health initiatives in localities considered by Public Health England to have a high prevalence of hepatitis C.
To ask the Secretary of State for Health, what support is in place for the provision of public health initiatives in localities considered by Public Health England to have a high prevalence of hepatitis C.
Public Health England supports work on local prioritisation of hepatitis C services by producing factsheets for local government, publishing a template to support commissioning by estimating the number of people infected with hepatitis C locally and the costs of treatment. It has also published local liver profiles at local authority level which includes, key local statistics and prevention guidance on hepatitis C and questions for local authority Health and Wellbeing Boards to consider.
To ask the Secretary of State for Health, what financial incentives are available for primary and secondary public health providers for screening programmes to improve diagnosis rates of hepatitis C in (a) localities considered by Public Health England to have a high prevalence of hepatitis C and (b) Cheshire.
To ask the Secretary of State for Health, what financial incentives are available for primary and secondary public health providers for screening programmes to improve diagnosis rates of hepatitis C in (a) localities considered by Public Health England to have a high prevalence of hepatitis C and (b) Cheshire.
There are currently no national direct financial incentives for screening programmes to improve the diagnostic rates for hepatitis C. However, NHS England sub-regions, working with other commissioners, have the ability to implement local incentives to improve diagnosis. The Department does not hold any information about any such local incentives that might have been put in place, including Cheshire.
On behalf of all Members, I thank the Secretary of State for the outstanding tone and substance of the statement. I hope the Solicitors Regulation Authority will restore some standing to the profession of which I am a member, as we are all ashamed of the actions of certain members...
On behalf of all Members, I thank the Secretary of State for the outstanding tone and substance of the statement. I hope the Solicitors Regulation Authority will restore some standing to the profession of which I am a member, as we are all ashamed of the actions of certain members...
In supporting the motion, as I think broadly we are across the House, does the right hon. Gentleman agree that one of the lessons from the 2003 intervention in Iraq is that we should have designed in the reconstruction of Iraq as a democratic state from the outset, rather than...
In supporting the motion, as I think broadly we are across the House, does the right hon. Gentleman agree that one of the lessons from the 2003 intervention in Iraq is that we should have designed in the reconstruction of Iraq as a democratic state from the outset, rather than...
My right hon. Friend is making an important point about the economic levers that need to be deployed. Does he agree that there is a serious dichotomy? Some of the middle
east coalition allies in the current arrangement also fund the export of undesirable aspects of Islamic fundamentalism, particularly to...
My right hon. Friend is making an important point about the economic levers that need to be deployed. Does he agree that there is a serious dichotomy? Some of the middle
east coalition allies in the current arrangement also fund the export of undesirable aspects of Islamic fundamentalism, particularly to...
The hon. Lady is making an important point, and although today’s debate is about enshrining spending on overseas aid in legislation, for agricultural prioritisation in DFID we need a unity of approach that recognises that not only protecting small holders but increasing farming is the way forward. Until there is...
The hon. Lady is making an important point, and although today’s debate is about enshrining spending on overseas aid in legislation, for agricultural prioritisation in DFID we need a unity of approach that recognises that not only protecting small holders but increasing farming is the way forward. Until there is...
I draw the House’s attention to my entry in the Register of Members’ Financial Interests relating to some of the subjects covered in the Bill.
I warmly welcome the Bill and congratulate its promoter and sponsors on bringing it forward. Having introduced a couple of private Members’ Bills in the past,...
I draw the House’s attention to my entry in the Register of Members’ Financial Interests relating to some of the subjects covered in the Bill.
I warmly welcome the Bill and congratulate its promoter and sponsors on bringing it forward. Having introduced a couple of private Members’ Bills in the past,...
I am grateful to my right hon. Friend for that, and for his expertise in understanding the procedures of this House and its relationship with the representational accountability we have as constituency Members. He is right to say that the pressure involved here is on not allowing the courts to...
I am grateful to my right hon. Friend for that, and for his expertise in understanding the procedures of this House and its relationship with the representational accountability we have as constituency Members. He is right to say that the pressure involved here is on not allowing the courts to...